Technical Analysis for MNOV - MediciNova, Inc.

Grade Last Price % Change Price Change
grade B 10.61 -16.39% -2.08
MNOV closed down 16.39 percent on Monday, May 20, 2019, on 2.8 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical MNOV trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
New Downtrend Bearish 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Slingshot Bullish Bullish Swing Setup -16.39%
Overbought Stochastic Strength -16.39%
New 52 Week Closing High Bullish -19.74%
New 52 Week High Strength -19.74%
Earnings Movers Other -19.74%

Older signals for MNOV ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company's principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
Medicine Health Pain Medication Multiple Sclerosis Respiratory Therapy Asthma Serious Diseases Central Nervous System Disorders Pulmonology Solid Tumor Cancers Urinary Incontinence Interstitial Cystitis
Is MNOV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.37
52 Week Low 6.68
Average Volume 112,908
200-Day Moving Average 9.9165
50-Day Moving Average 10.1932
20-Day Moving Average 11.8145
10-Day Moving Average 12.437
Average True Range 0.666
ADX 35.95
+DI 27.8507
-DI 36.5219
Chandelier Exit (Long, 3 ATRs ) 11.372
Chandelier Exit (Short, 3 ATRs ) 11.117999999999999
Upper Bollinger Band 13.4475
Lower Bollinger Band 10.1815
Percent B (%b) 0.13
BandWidth 27.643997
MACD Line 0.6169
MACD Signal Line 0.7326
MACD Histogram -0.1157
Fundamentals Value
Market Cap 372.07 Million
Num Shares 35.1 Million
EPS -0.29
Price-to-Earnings (P/E) Ratio -36.59
Price-to-Sales 0.00
Price-to-Book 6.66
PEG Ratio -0.91
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.68
Resistance 3 (R3) 11.69 11.34 11.50
Resistance 2 (R2) 11.34 11.07 11.34 11.44
Resistance 1 (R1) 10.98 10.90 10.81 10.97 11.38
Pivot Point 10.63 10.63 10.55 10.63 10.63
Support 1 (S1) 10.27 10.36 10.10 10.26 9.84
Support 2 (S2) 9.92 10.19 9.92 9.78
Support 3 (S3) 9.56 9.92 9.72
Support 4 (S4) 9.55